“We built our company based on a strong team-oriented values system, and we see a great fit with the Mesa culture. “Our robust technology platform along with deep customer partnership has been the foundation of our success,” Dansky said. 31, 2021.Īgena Bio’s CEO, Pete Dansky will head up the new Clinical Genomics Division at Mesa. The transaction is expected to be completed by the end of this year during Mesa’s third fiscal quarter ending Dec. Agena is a private molecular diagnostics tools company that develops, manufactures and supplies highly sensitive, low-cost, high-throughput, genetic analysis solutions.Īt the close of the deal, Agena will remain in San Diego and become Mesa Lab’s new Clinical Genomics Division. that designs and manufactures critical quality control solutions for the pharmaceutical, healthcare and medical device industries. Mesa Labs is a public company based in Lakewood, Colo. The deal is an all-cash transaction funded by Mesa’s cash on-hand and proceeds from its credit facilities, according to the Sept.
(NASDAQ:MLAB) for a purchase price of $300 million. agreed to be acquired by Mesa Laboratories, Inc.
0 kommentar(er)
